-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Pardes Biosciences (NASDAQ:PRDS) PT Lowered to $9.00
Pardes Biosciences (NASDAQ:PRDS) PT Lowered to $9.00
Pardes Biosciences (NASDAQ:PRDS – Get Rating) had its price objective dropped by investment analysts at SVB Leerink from $12.00 to $9.00 in a research report issued on Friday, Benzinga reports. The firm currently has an "outperform" rating on the stock. SVB Leerink's target price indicates a potential upside of 426.32% from the company's previous close.
Separately, JMP Securities began coverage on Pardes Biosciences in a research note on Tuesday, December 13th. They set a "market outperform" rating and a $9.00 price target for the company.
Get Pardes Biosciences alerts:Pardes Biosciences Price Performance
Pardes Biosciences stock opened at $1.71 on Friday. Pardes Biosciences has a one year low of $0.75 and a one year high of $13.01. The business has a fifty day moving average of $1.45 and a two-hundred day moving average of $2.06.
Pardes Biosciences (NASDAQ:PRDS – Get Rating) last released its quarterly earnings results on Monday, November 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.09. On average, analysts expect that Pardes Biosciences will post -1.77 earnings per share for the current fiscal year.Institutional Trading of Pardes Biosciences
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp purchased a new stake in Pardes Biosciences in the 1st quarter valued at about $75,000. American International Group Inc. acquired a new position in Pardes Biosciences during the 2nd quarter worth approximately $41,000. Virtu Financial LLC acquired a new position in Pardes Biosciences during the 3rd quarter worth approximately $25,000. Dynamic Technology Lab Private Ltd acquired a new position in Pardes Biosciences during the 1st quarter worth approximately $105,000. Finally, JPMorgan Chase & Co. acquired a new position in Pardes Biosciences during the 2nd quarter worth approximately $47,000.
About Pardes Biosciences
(Get Rating)
Pardes Biosciences, Inc, a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases.
Read More
- Get a free copy of the StockNews.com research report on Pardes Biosciences (PRDS)
- EVs, Robotics Among Growth Drivers As Chipmaker STMicro Gaps Up
- Does Oil Services Firm NOV Have Enough Energy To Maintain Rally?
- Shopify Clears Cup-With-Handle Base: Can Momentum Continue?
- The Future Of E-Commerce: Analysis And New Data
- Chevron Delights Shareholders with $75 Billion in Share Buybacks
Receive News & Ratings for Pardes Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pardes Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
Pardes Biosciences (NASDAQ:PRDS – Get Rating) had its price objective dropped by investment analysts at SVB Leerink from $12.00 to $9.00 in a research report issued on Friday, Benzinga reports. The firm currently has an "outperform" rating on the stock. SVB Leerink's target price indicates a potential upside of 426.32% from the company's previous close.
Pardes Biosciences(纳斯达克股票代码:PRDS — 获取评级) Benzinga报道,在周五发布的一份研究报告中,SVB Leerink的投资分析师将其价格目标从12.00美元降至9.00美元。该公司目前对该股的评级为 “跑赢大盘”。SVB Leerink的目标价格表明,与该公司之前的收盘价相比,潜在的上涨空间为426.32%。
Separately, JMP Securities began coverage on Pardes Biosciences in a research note on Tuesday, December 13th. They set a "market outperform" rating and a $9.00 price target for the company.
另外,JMP Securities在12月13日星期二的一份研究报告中开始报道Pardes Biosciences。他们为公司设定了 “市场跑赢大盘” 的评级和9.00美元的目标价格。
Pardes Biosciences Price Performance
帕德斯生物科学价格表现
Pardes Biosciences stock opened at $1.71 on Friday. Pardes Biosciences has a one year low of $0.75 and a one year high of $13.01. The business has a fifty day moving average of $1.45 and a two-hundred day moving average of $2.06.
Pardes Biosciences股票周五开盘价为1.71美元。Pardes Biosciences创下了0.75美元的一年低点和13.01美元的一年高点。该公司的五十天移动平均线为1.45美元,两百天移动平均线为2.06美元。
Institutional Trading of Pardes Biosciences
帕德斯生物科学的机构交易
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp purchased a new stake in Pardes Biosciences in the 1st quarter valued at about $75,000. American International Group Inc. acquired a new position in Pardes Biosciences during the 2nd quarter worth approximately $41,000. Virtu Financial LLC acquired a new position in Pardes Biosciences during the 3rd quarter worth approximately $25,000. Dynamic Technology Lab Private Ltd acquired a new position in Pardes Biosciences during the 1st quarter worth approximately $105,000. Finally, JPMorgan Chase & Co. acquired a new position in Pardes Biosciences during the 2nd quarter worth approximately $47,000.
一些对冲基金和其他机构投资者最近增加了或减少了在该业务中的股份。纽约银行梅隆公司在第一季度收购了Pardes Biosciences的新股份,价值约7.5万美元。美国国际集团公司在第二季度收购了Pardes Biosciences的新职位,价值约41,000美元。Virtu Financial LLC在第三季度收购了Pardes Biosciences的新职位,价值约25,000美元。Dynamic Technology Lab Private Ltd在第一季度收购了帕德斯生物科学的新职位,价值约10.5万美元。最后,摩根大通在第二季度收购了Pardes Biosciences的新职位,价值约47,000美元。
About Pardes Biosciences
关于帕德斯生物科学
(Get Rating)
(获取评分)
Pardes Biosciences, Inc, a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases.
Pardes Biosciences, Inc是一家临床阶段的生物制药公司,专注于发现、开发和商业化新疗法,以改善患有危及生命的疾病患者的生活。其主要候选药物是 PBI-0451,它处于临床开发阶段,用于治疗和预防严重的急性呼吸系统综合征冠状病毒 2 感染和相关疾病。
Read More
阅读更多
- Get a free copy of the StockNews.com research report on Pardes Biosciences (PRDS)
- EVs, Robotics Among Growth Drivers As Chipmaker STMicro Gaps Up
- Does Oil Services Firm NOV Have Enough Energy To Maintain Rally?
- Shopify Clears Cup-With-Handle Base: Can Momentum Continue?
- The Future Of E-Commerce: Analysis And New Data
- Chevron Delights Shareholders with $75 Billion in Share Buybacks
- 免费获取 StockNews.com 关于 Pardes Biosciences (PRDS) 的研究报告
- 随着芯片制造商意法半导体的差距扩大,电动汽车、机器人是增长驱动力之一
- 石油服务公司NOV有足够的能量来维持涨势吗?
- Shopify 清理了带手柄的杯子底座:势头能否持续下去?
- 电子商务的未来:分析和新数据
- 雪佛龙通过750亿美元的股票回购使股东感到高兴
Receive News & Ratings for Pardes Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pardes Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接收《帕德斯生物科学日报》的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Pardes Biosciences及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧